Blackrock Funds · net assets $6.37B · 137 holdings as of August 31, 2026. Monthly N-PORT disclosure: the full book, not just equities.
EC: 98.3% · STIV: 1.7% · OTHER: 0.0% · EP: 0.0% · DE: 0.0%
| Month 1 | Month 2 | Month 3 | |
|---|---|---|---|
| Sales | $46.8M | $44.3M | $40.3M |
| Reinvestment | $0 | $541M | $0 |
| Redemptions | $158M | $169M | $104M |
| Net realized gain (non-derivative) | $80.7M | $128M | $55.7M |
| Net unrealized appreciation (non-derivative) | $336M | $-104M | $296M |
The three months of the reporting period, as filed; month 3 ends August 31, 2026.
| Holding | Value | % of net assets |
|---|---|---|
| Eli Lilly & Company EC | $760M | 11.92% |
| Johnson & Johnson EC | $512M | 8.03% |
| Merck & Company Inc EC | $355M | 5.56% |
| Abbvie Inc EC | $323M | 5.07% |
| Thermo Fisher Scientific Inc EC | $281M | 4.41% |
| Unitedhealth Group Inc EC | $276M | 4.33% |
| Gilead Sciences Inc EC | $261M | 4.09% |
| Amgen Inc EC | $254M | 3.98% |
| Vertex Pharmaceuticals Inc EC | $212M | 3.33% |
| Abbott Laboratories EC | $175M | 2.74% |
| Pfizer Inc EC | $153M | 2.40% |
| Danaher Corp EC | $146M | 2.29% |
| Edwards Lifesciences Corp EC | $145M | 2.27% |
| Elevance Health Inc EC | $119M | 1.86% |
| Stryker Corp EC | $115M | 1.80% |
| Bristol-myers Squibb Company EC | $113M | 1.77% |
| Argenx Se EC | $98.1M | 1.54% |
| Biogen Inc EC | $78.9M | 1.24% |
| Teva Pharmaceutical Industries Ltd EC | $77.2M | 1.21% |
| Blackrock Funds Iii STIV | $74.5M | 1.17% |
| Revolution Medicines Inc EC | $74.3M | 1.17% |
| Waters Corp EC | $72.3M | 1.13% |
| Iqvia Holdings Inc EC | $68.6M | 1.08% |
| Moderna Inc EC | $62.4M | 0.98% |
| Illumina Inc EC | $60.8M | 0.95% |
| Dexcom Inc EC | $60.4M | 0.95% |
| Boston Scientific Corp EC | $59.9M | 0.94% |
| Hca Healthcare Inc EC | $57.1M | 0.90% |
| Incyte Corp EC | $54.2M | 0.85% |
| Protagonist Therapeutics Inc EC | $48.2M | 0.76% |
| Cytokinetics Inc EC | $46.1M | 0.72% |
| Penumbra Inc EC | $43M | 0.68% |
| Agilent Technologies Inc EC | $41.7M | 0.65% |
| Tenet Healthcare Corp EC | $41M | 0.64% |
| Galderma Group Ag EC | $39M | 0.61% |
| Cencora Inc EC | $39M | 0.61% |
| Blackrock Liquidity Funds STIV | $37.1M | 0.58% |
| Insmed Inc EC | $36.5M | 0.57% |
| Cogent Biosciences Inc EC | $36.1M | 0.57% |
| Apogee Therapeutics Inc EC | $35.6M | 0.56% |
| Novartis Ag EC | $31.6M | 0.50% |
| Humana Inc EC | $28.9M | 0.45% |
| United Therapeutics Corp EC | $28.4M | 0.45% |
| Lb Pharmaceuticals Inc EC | $26.8M | 0.42% |
| Halozyme Therapeutics Inc EC | $26.2M | 0.41% |
| Tempus Ai Inc EC | $26.1M | 0.41% |
| Cvs Health Corp EC | $24.6M | 0.39% |
| Oruka Therapeutics Inc EC | $24.5M | 0.38% |
| Mckesson Corp EC | $24.4M | 0.38% |
| Bruker Corp EC | $22.9M | 0.36% |
| Erasca Inc EC | $22.6M | 0.35% |
| Rhythm Pharmaceuticals Inc EC | $21.3M | 0.33% |
| Biomarin Pharmaceutical Inc EC | $21M | 0.33% |
| Roivant Sciences Ltd EC | $21M | 0.33% |
| Mettler-toledo International Inc EC | $20.8M | 0.33% |
| Mbx Biosciences Inc EC | $20.5M | 0.32% |
| Quest Diagnostics Inc EC | $20.5M | 0.32% |
| Dianthus Therapeutics Inc EC | $19.7M | 0.31% |
| Neurocrine Biosciences Inc EC | $17.4M | 0.27% |
| Axsome Therapeutics Inc EC | $17.4M | 0.27% |
Showing top 60 of 137 holdings.
Loading...
